American Journal of Transplantation· 2017Q1
Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients
- 356citations
- Q1SCImago
- 2017year
Short summary
Tocilizumab, an anti-IL-6 receptor therapy, achieved 80% graft survival and 91% patient survival at 6 years in 36 HLA-sensitized kidney transplant recipients with chronic antibody-mediated rejection (cAMR) and transplant glomerulopathy (TG) who failed standard treatments.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine